XHANCE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XHANCE (XHANCE).
XHANCE (fluticasone propionate) is an anti-inflammatory corticosteroid that inhibits multiple inflammatory cell types and mediators (e.g., histamine, leukotrienes, cytokines) involved in nasal and sinus inflammation. It reduces nasal polyp size and nasal congestion.
| Metabolism | Fluticasone propionate is metabolized primarily by cytochrome P450 3A4 (CYP3A4) to an inactive carboxylic acid metabolite. |
| Excretion | Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% of the dose as unchanged drug; fecal excretion is minimal. |
| Half-life | Terminal half-life is approximately 2-3 hours; short half-life supports twice-daily dosing for sustained local effect. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.7 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Intranasal: systemic bioavailability is approximately 5-10% due to extensive first-pass metabolism; local nasal bioavailability is high. |
| Onset of Action | Intranasal: clinical effect (reduction in nasal congestion) observed within 12 hours of first dose. |
| Duration of Action | Intranasal: duration of clinical effect is approximately 12 hours; consistent with twice-daily dosing regimen. |
1 spray (93 mcg fluticasone propionate) per nostril twice daily (total daily dose 372 mcg). Intranasal route.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; caution in severe hepatic impairment due to potential increased systemic exposure. |
| Pediatric use | Not approved for pediatric patients aged <18 years; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use with caution due to potential increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for XHANCE (XHANCE).
| Breastfeeding | It is not known whether fluticasone propionate is excreted in human breast milk after intranasal administration. However, systemically administered corticosteroids are distributed into breast milk in small amounts (e.g., prednisolone M/P ratio ~0.12). Given minimal systemic absorption of intranasal fluticasone (absolute bioavailability <2%), the amount in breast milk is expected to be negligible. Caution is advised, but the risk to the nursing infant is likely low. |
| Teratogenic Risk | XHANCE (fluticasone propionate) is an intranasal corticosteroid. In animal reproduction studies, fluticasone propionate caused teratogenic effects (cleft palate, skeletal abnormalities) at subcutaneous doses 1-5 times the maximum recommended human daily intranasal dose (MRHDID) in mice and 5 times in rats, but no teratogenic effects were observed in rabbits at 2.5 times MRHDID. However, there are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, XHANCE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Systemic absorption after intranasal administration is minimal, reducing fetal exposure. First trimester risk is unknown; second and third trimester risks are low based on minimal systemic bioavailability. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component of the product","Recent nasal surgery or nasal trauma (until wound healing is complete)"]
| Precautions | ["Risk of HPA axis suppression with prolonged or high-dose use","Increased susceptibility to infections (e.g., chickenpox, measles) due to immunosuppression","Potential for growth suppression in children (though not indicated for pediatric use)","Local nasal effects: epistaxis, nasal septal perforation, Candida albicans infection","Impaired wound healing after nasal surgery","Glaucoma and cataracts with prolonged use"] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is routinely required for intranasal fluticasone propionate during pregnancy. However, standard prenatal care should include monitoring of fetal growth and development, especially if the patient uses other corticosteroids concurrently. In animal studies, high systemic doses were associated with fetal growth restriction; thus, in cases of prolonged or high-dose use, consider periodic fetal ultrasound to assess growth. |
| Fertility Effects | There is no known effect of intranasal fluticasone propionate on human fertility. In animal studies, fluticasone propionate had no adverse effects on fertility in rats at subcutaneous doses up to 50 mcg/kg/day (approximately 1.5 times MRHDID based on body surface area). No human data are available. |